In LDD patients, the hypermethylated PARK2 promoter and the related inhibited PARK2 expression can reduce proteasomal degradation, thus altering the normal cellular environment in intervertebral disc cells, with the increased degradation of intervertebral disc tissue. The gene discussed is PRKN; the disease is Lhermitte-Duclos disease.